Home > Riviste > Minerva Anestesiologica > Fascicoli precedenti > Minerva Anestesiologica 2022 June;88(6) > Minerva Anestesiologica 2022 June;88(6):516-23

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

EXPERTS’ OPINION   Free accessfree

Minerva Anestesiologica 2022 June;88(6):516-23

DOI: 10.23736/S0375-9393.22.16283-8

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

What’s new on the management of obstetric patients who tested positive for COVID-19?

Carla GIORGINI, Rachele SIMONTE, Gianmaria CAMMAROTA, Edoardo DE ROBERTIS

Division of Anesthesia, Analgesia, and Intensive Care, Department of Medicine and Surgery, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy



To date, there is still partial data on the effects of COVID-19 on pregnant women. The constant collection of information results in a continuous updating of the knowledge about the best management of pregnant patients affected by COVID-19. This work aimed to summarize the state of the art on prevention and management of SARS-CoV-2 infection in obstetric patients. This was enabled by a comprehensive literature search for the most recent and relevant publications on the subject, including guidelines and recommendations. Management of these women by a multidisciplinary team is of crucial importance, given the extreme clinical complexity of this condition. Every health worker involved must put in place all possible procedures to protect themselves from contagion. Neuraxial anesthesia should be favored in the management of labor and caesarean section over other modalities, unless there are contraindications based on the patient’s status. There is still no standardized drug treatment in pregnant women with COVID-19 due to their exclusion from studies conducted to evaluate pharmacological therapies. Nevertheless, various drugs have been used to treat this disease in pregnancy, although the data at our disposal are still few. As regards mRNA vaccines, it seems that their immunogenicity, safety and tolerability in pregnant women are comparable to those of non-pregnant women of the same age. More studies are certainly needed in infected pregnant women to establish treatment and prevention protocols for this special category of patients.


KEY WORDS: COVID-19; Pregnancy complications; Anesthesia, obstetrical; SARS-CoV-2

inizio pagina